Low-dose steroids for kidney disease from vasculitis
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new or returning case of a type of vasculitis called GPA or MPA, with a positive blood test for MPO or PR3 antibodies.
- Your kidneys are severely involved, shown by a low kidney function test (eGFR less than 40) and either a kidney biopsy with certain changes or blood in your urine with abnormal red blood cell shapes.
- You haven't been on dialysis for more than 21 days just before the trial starts, and you haven't had a kidney transplant.
- You are at least 18 years old and not pregnant at the screening visit.
- You haven't received more than one IV dose or 14 days of certain strong treatments (like cyclophosphamide or high-dose steroids) in the month before the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
Hear when a new Granulomatosis With Polyangiitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.